Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent B-cell Lymphomas”

223 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 223 results

Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)WithdrawnNCT00003605
What this trial is testing

Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Study completedNCT01206777
What this trial is testing

Feasibility Study of a 60 Minute Rapid Infusion Rituximab Protocol in Patients With B-cell Malignancies

Who this might be right for
Indolent or Intermediate Grade B-cell Malignancy
Ohio State University Comprehensive Cancer Center 52
Early research (Phase 1)Study completedNCT00052416
What this trial is testing

Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
LeukemiaLymphoma
Beth Israel Deaconess Medical Center
Testing effectiveness (Phase 2)Study completedNCT00880581
What this trial is testing

Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinLymphomaLymphomas: Non-Hodgkin Follicular / Indolent B-Cell+1 more
Ronald Levy 30
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)WithdrawnNCT07030699
What this trial is testing

Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00720876
What this trial is testing

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
City of Hope Medical Center 30
Testing effectiveness (Phase 2)Ended earlyNCT02898259
What this trial is testing

Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma

Who this might be right for
B Cell LymphomaLymphoma
Brian Hill 19
Not applicableUnknownNCT05803395
What this trial is testing

Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent B-Cell Non-Hodgkin LymphomaCOVID-19
Gruppo Italiano Malattie EMatologiche dell'Adulto 954
Testing effectiveness (Phase 2)Study completedNCT00052572
What this trial is testing

Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 35
Testing effectiveness (Phase 2)Study completedNCT00295932
What this trial is testing

Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 79
Testing effectiveness (Phase 2)Study completedNCT02362035
What this trial is testing

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Who this might be right for
Follicular Lymphoma (FL)CLLSmall Lymphocytic Lymphoma (SLL)+10 more
Acerta Pharma BV 161
Testing effectiveness (Phase 2)Study completedNCT00895661
What this trial is testing

High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas

Who this might be right for
B-cell LymphomaIndolent B-cell Lymphoma
Massachusetts General Hospital 40
Early research (Phase 1)Ended earlyNCT00473551
What this trial is testing

Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies

Who this might be right for
LeukemiaLymphomaMyeloma
M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Early research (Phase 1)Study completedNCT01088048
What this trial is testing

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma
Gilead Sciences 241
Large-scale testing (Phase 3)Ended earlyNCT02626455
What this trial is testing

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 551
Early research (Phase 1)Study completedNCT03985189
What this trial is testing

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03198026
What this trial is testing

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Who this might be right for
Non-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular Lymphoma+16 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 30
Load More Results